🎉 M&A multiples are live!
Check it out!

OptiNose Valuation Multiples

Discover revenue and EBITDA valuation multiples for OptiNose and similar public comparables like Vivoryon Therapeutics, Julphar, and Pharming.

OptiNose Overview

About OptiNose

OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.


Founded

2010

HQ

United States of America
Employees

128

Website

optinose.com

Financials

LTM Revenue $84.5M

LTM EBITDA n/a

EV

$137M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

OptiNose Financials

OptiNose has a last 12-month revenue of $84.5M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, OptiNose achieved revenue of $78.2M and an EBITDA of -$1.2M.

OptiNose expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See OptiNose valuation multiples based on analyst estimates

OptiNose P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $71.0M $78.2M XXX XXX XXX
Gross Profit $67.0M $62.4M XXX XXX XXX
Gross Margin 94% 80% XXX XXX XXX
EBITDA -$15.6M -$1.2M XXX XXX XXX
EBITDA Margin -22% -2% XXX XXX XXX
Net Profit -$74.8M -$35.5M XXX XXX XXX
Net Margin -105% -45% XXX XXX XXX
Net Debt $34.3M $56.5M XXX XXX XXX

Financial data powered by Morningstar, Inc.

OptiNose Stock Performance

As of April 15, 2025, OptiNose's stock price is $9.

OptiNose has current market cap of $92.1M, and EV of $137M.

See OptiNose trading valuation data

OptiNose Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$137M $92.1M XXX XXX XXX XXX $-2.24

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

OptiNose Valuation Multiples

As of April 15, 2025, OptiNose has market cap of $92.1M and EV of $137M.

OptiNose's trades at 1.6x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate OptiNose's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for OptiNose and 10K+ public comps

OptiNose Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $137M XXX XXX XXX
EV/Revenue 1.7x XXX XXX XXX
EV/EBITDA -114.0x XXX XXX XXX
P/E -4.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -3.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get OptiNose Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

OptiNose Valuation Multiples

OptiNose's NTM/LTM revenue growth is 23%

OptiNose's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $0.7M for the same period.

Over next 12 months, OptiNose's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate OptiNose's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for OptiNose and other 10K+ public comps

OptiNose Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 10% XXX XXX XXX XXX
EBITDA Margin -2% XXX XXX XXX XXX
EBITDA Growth -92% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 21% XXX XXX XXX XXX
Revenue per Employee $0.6M XXX XXX XXX XXX
Opex per Employee $0.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 5% XXX XXX XXX XXX
Opex to Revenue 112% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

OptiNose Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

OptiNose M&A and Investment Activity

OptiNose acquired  XXX companies to date.

Last acquisition by OptiNose was  XXXXXXXX, XXXXX XXXXX XXXXXX . OptiNose acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by OptiNose

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About OptiNose

When was OptiNose founded? OptiNose was founded in 2010.
Where is OptiNose headquartered? OptiNose is headquartered in United States of America.
How many employees does OptiNose have? As of today, OptiNose has 128 employees.
Who is the CEO of OptiNose? OptiNose's CEO is Dr. Ramy A. Mahmoud, M.D..
Is OptiNose publicy listed? Yes, OptiNose is a public company listed on NAS.
What is the stock symbol of OptiNose? OptiNose trades under OPTN ticker.
When did OptiNose go public? OptiNose went public in 2017.
Who are competitors of OptiNose? Similar companies to OptiNose include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of OptiNose? OptiNose's current market cap is $92.1M
What is the current revenue of OptiNose? OptiNose's last 12-month revenue is $84.5M.
What is the current EV/Revenue multiple of OptiNose? Current revenue multiple of OptiNose is 1.6x.
What is the current revenue growth of OptiNose? OptiNose revenue growth between 2023 and 2024 was 10%.
Is OptiNose profitable? Yes, OptiNose is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.